Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas

Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas

Abstract Neurofibromatosis type 1 (NF1), the most common tumor predisposition syndrome, occurs when NF1 gene variants result in loss of neurofibromin, a negative regulator of RAS activity. Plexiform neurofibromas (PN) are peripheral nerve sheath tumors that develop in patients with NF1 and are assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Amy E. Armstrong, Allan J. Belzberg, John R. Crawford, Angela C. Hirbe, Zhihong J. Wang
Formato: Artículo
Lenguaje:English
Publicado: BMC 2023-06-01
Colección:BMC Cancer
Materias:
Neurofibromatosis type 1
Plexiform neurofibroma
MEK inhibitors
Surgery
Clinical decision making
Acceso en línea:https://doi.org/10.1186/s12885-023-10996-y

Internet

https://doi.org/10.1186/s12885-023-10996-y

Ejemplares similares